Axsome Therapeutics (AXSM) has drawn investor attention after recent trading, with the stock last closing at $241.67 and the company reporting annual revenue of $708.236 million alongside a net loss of $188.303 million.

The recent 1 day share price return of 1.83% and 90 day share price return of 50.57% sit alongside a 1 year total shareholder return of 133.81%. This pattern suggests momentum has been building over both shorter and longer horizons.

If Axsome Therapeutics has caught your eye, this can be a good moment to look across the sector and see how other healthcare AI opportunities stack up using the 39 healthcare AI stocks

With Axsome Therapeutics posting US$708.236 million in revenue alongside a net loss of US$188.303 million and a strong recent share price run, you have to ask: is there still upside on the table, or is the market already pricing in future growth?

Most Popular Narrative: 12.6% Undervalued

Axsome Therapeutics is trading at $241.67 against a widely followed fair value estimate of $276.47, and that gap is built on a detailed earnings and revenue story.

The company is advancing multiple late-stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications), which positions Axsome to benefit from the aging population and rising prevalence of CNS disorders, potentially resulting in a diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.

Curious what earnings curve, margin shift, and valuation multiple are baked into that $276.47 figure? The narrative leans on aggressive top line expansion and a sharp swing in profitability that goes well beyond today’s reported loss.

Result: Fair Value of $276.47 (UNDERVALUED)

However, Axsome Therapeutics still faces meaningful risks, including reliance on Auvelity and Sunosi for most revenue and continued net losses, despite US$708.236 million in annual sales.

Another View: What Axsome Therapeutics’ Sales Multiple Is Telling You

The earlier fair value narrative paints Axsome Therapeutics as 12.6% undervalued, yet the current P/S ratio of 17.6x is far above the US Pharmaceuticals industry at 5.8x and the peer average at 4.8x. Even with a fair ratio of 18x, that gap points to real valuation risk if expectations soften.

Next Steps

The mixed signals around Axsome Therapeutics make it a stock that invites closer inspection. Move quickly, review the full picture and weigh up its 2 key rewards

Looking for more investment ideas beyond Axsome Therapeutics?

If Axsome Therapeutics has your attention, do not stop here; broaden your watchlist using focused stock screeners that surface different types of opportunities in seconds.

• Spot potential value opportunities ahead of the crowd by scanning 44 high quality undervalued stocks that combine quality fundamentals with room for a re-rating.
• Strengthen the defensive side of your portfolio by reviewing 71 resilient stocks with low risk scores designed to highlight companies with more resilient profiles.
• Stay early on potential future leaders by working through the screener containing 19 high quality undiscovered gems before they attract wider market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.